The Sputum Microbiome in Chronic Obstructive Pulmonary Disease Exacerbations

Area of Science:

• Microbiology
• Pulmonology
• Genomics

Background:

• Acute exacerbations of chronic obstructive pulmonary disease (COPD) are linked to accelerated lung function decline.
• Previous studies indicate significant alterations in the bronchial microbiome of COPD patients.
• Limited research exists on microbiome changes during community-acquired COPD exacerbations.

Purpose of the Study:

• To investigate changes in the bronchial bacterial microbiome during COPD exacerbations.
• To analyze the impact of exacerbation treatments on microbiome recovery.

Main Methods:

• Longitudinal cohort study of COPD patients.
• Sputum sample analysis using culture-independent 16S rRNA sequencing.
• In silico inference of metagenomic functions.

Main Results:

• Sputum bacterial composition remained stable during stable COPD but changed during exacerbations.
• Exacerbations showed enrichment of typical COPD pathogens (e.g., Haemophilus influenzae) and related species.
• Beneficial bacteria with anti-inflammatory functions were depleted during exacerbations.
• Corticosteroid treatment led to microbiome enrichment, while antibiotics alone caused prolonged suppression.
• Microbiome recovery rates varied significantly based on prescribed exacerbation treatments.

Conclusions:

• COPD exacerbations cause heterogeneous bronchial microbiome changes, increasing pathogens and decreasing homeostatic bacteria.
• Exacerbation treatments differentially affect the bronchial microbiome's return to baseline composition.
• Understanding these microbiome dynamics is crucial for managing COPD exacerbations.